Last reviewed · How we verify

NCT07526649: COOLHEAD-2B

Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b)

Not yet recruiting NA Last updated 13 April 2026
What this trial tests

NA trial testing Non-invasive convective head cooling in Stroke in 182 participants. Not yet recruiting.

Timeline
10 April 2026
Primary endpoint
31 December 2028
30 June 2029

Quick facts

Lead sponsorAuckland City Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment182
Start date10 April 2026
Primary completion31 December 2028
Estimated completion30 June 2029
Sites1 location across New Zealand

Drugs / interventions tested

Conditions studied

Sponsor

Auckland City Hospital

Who can join

18 and older, any sex, with Stroke or Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Auckland City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07526649.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing